Background: In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P ¼ 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs) in the coBRIM study.
Introduction
Targeted therapies have revolutionized the management of advanced BRAF-mutated melanoma, specifically BRAF inhibitors (BRAFi) such as vemurafenib and dabrafenib and MEK inhibitors (MEKi) such as cobimetinib and trametinib. Combination regimens of BRAFi and MEKi have improved clinical benefit compared with either BRAFi or MEKi monotherapy, and cobimetinib plus vemurafenib [1] [2] [3] [4] and dabrafenib plus trametinib [5] [6] [7] [8] combinations are approved for the management of metastatic melanoma.
In the coBRIM study, cobimetinib plus vemurafenib significantly improved progression-free survival [PFS; hazard ratio (HR), 0.58; 95% confidence interval (CI) 0.46-0.72; P < 0.001] and overall survival (OS; HR, 0.70; 95% CI 0.55-0.90; P ¼ 0.005) compared with placebo plus vemurafenib (hereafter referred to as vemurafenib), with a tolerable and manageable safety profile [9, 10] . Common adverse events (AEs) that occurred during treatment with the cobimetinib plus vemurafenib regimen included rash, photosensitivity, serous retinopathy, cutaneous squamous cell carcinoma (cuSCC), diarrhoea, pyrexia, left ventricular ejection fraction (LVEF) decline, abnormal liver function tests (LFTs), and elevated creatinine phosphokinase [11, 12] . We describe the clinical course, management, and resolution of these key AEs in patients treated with cobimetinib plus vemurafenib in the coBRIM study.
Patients and methods

Study design and treatment
coBRIM is an international, randomized, double-blind, placebo-controlled phase III study evaluating the safety and efficacy of cobimetinib plus vemurafenib compared with vemurafenib in adults with advanced BRAF V600 mutation-positive melanoma [10] . Patients were randomly assigned to receive oral vemurafenib (960 mg twice a day) with either oral cobimetinib (60 mg once a day for 21 days, followed by 7 days off) or placebo until disease progression, unacceptable toxicity or withdrawal of consent. The study was approved by the institutional review board or ethics committee at each participating institution and was conducted in accordance with the provisions of the Declaration of Helsinki and the International Conference on Harmonisation guidelines for Good Clinical Practice. All patients provided written informed consent.
Safety assessments
In addition to standard safety evaluations, all patients underwent ophthalmic, cardiac, and dermatologic surveillance examinations (supplementary Table S1 , available at Annals of Oncology online). AEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Analysis
The safety-evaluable population included all patients who received !1 dose of study treatment. Results use descriptive statistics. Data cut-off date was 30 September 2015.
Results
Patients
Of 495 patients recruited, 493 patients received treatment and constituted the safety population (cobimetinib plus vemurafenib, n ¼ 247; vemurafenib, n ¼ 246). Baseline characteristics have been reported [9, 10] . At data cut-off (30 September 2015), the median follow-up duration was 18.5 months.
Summary of AEs
The most common any-grade AEs (reported in !25% of patients in any arm) included rash, photosensitivity, serous retinopathy, alopecia, hyperkeratosis, diarrhoea, nausea, arthralgia, fatigue, vomiting, blood creatine phosphokinase (CPK) increase, and alanine aminotransferase (ALT) increase (Table 1) . AEs (any grade) reported more frequently (!10% difference) in the cobimetinib plus vemurafenib arm compared with the vemurafenib arm included blood CPK increase (þ32.4%), diarrhoea (þ27.4%), serous retinopathy (þ23.4%), nausea (þ16.5%), aspartate aminotransferase (AST) increase and vomiting (þ11.7% for each), and photosensitivity (þ10%). In contrast, patients treated with vemurafenib reported a higher incidence of hyperkeratosis (þ17.1%) and alopecia (þ13.9%).
AEs (grade !3) that occurred more frequently (!5% difference) in the cobimetinib plus vemurafenib arm compared with the vemurafenib arm included AST increase (þ6.9%), diarrhoea (þ5.7%), and ALT increase (þ5.2%), whereas patients treated with vemurafenib reported a higher incidence of cuSCC (þ9%) and keratoacanthoma (þ7.3%). Among clinically significant liver laboratory abnormalities, 2 of the 472 patients (0.4%; 1 patient in each arm) experienced AST >3Â upper limit of normal (ULN) plus bilirubin >2Â ULN and 4 of 475 patients (0.8%; 2 patients in each arm) experienced ALT >3Â ULN plus bilirubin >2Â ULN.
Time to onset of AEs of interest and recurrence
The most common AEs of clinical interest, including rash, diarrhoea, pyrexia, blood CPK increase, and abnormal LFTs [ALT, AST, and cglutamyltransferase level (GGT) increase], reported with the combination regimen of cobimetinib plus vemurafenib had an early onset, with the majority of patients experiencing these events within the first three cycles of treatment ( Figure 1 and supplementary Figure S1 , available at Annals of Oncology online). This is consistent with a median time to onset of <1 month after starting treatment with cobimetinib plus vemurafenib for all of these AEs, with the exception of LFT abnormalities for which the median time to onset was slightly longer (1.4 months; Figure 2) . A similar time to onset was observed for rash, pyrexia, blood CPK increase, and abnormal LFTs in the vemurafenib arm ( Figure 2 and supplementary Figure S2 , available at Annals of Oncology online). The median time to onset of diarrhoea in the vemurafenib arm was longer than in the cobimetinib plus vemurafenib arm (2.1 versus 0.4 months, respectively; Figure 2 and supplemen tary Figure S2 , available at Annals of Oncology online).
In contrast, no apparent temporal pattern was observed for photosensitivity, serous retinopathy and the less frequently reported AEs of cuSCC, keratoacanthoma, and LVEF decline in patients treated with cobimetinib plus vemurafenib ( Figure 1 and supplementary Figure S1 , available at Annals of Oncology online). These AEs were typically characterized by a median onset of 2-5 months in the cobimetinib plus vemurafenib arm ( Figure 2 ) and random frequency over the treatment period ( Figure 1 and sup plementary Figure S1 , available at Annals of Oncology online). For serous retinopathy in the cobimetinib plus vemurafenib arm, the incidence was highest in the first two cycles ( Figure 1F ), reflecting mostly asymptomatic (grade 1) events identified by ophthalmologic surveillance. A second cluster of events also coincided with scheduled ophthalmologic examinations. Notably, the median times to onset for photosensitivity, cuSCC, and LVEF decline were earlier in the vemurafenib arm compared with those observed in the cobimetinib plus vemurafenib arm (Figure 2 ). In addition, incidence data by cycle show that early occurrence of cuSCC and keratoacanthoma was less common in patients receiving cobimetinib plus vemurafenib ( Figure 1 and supplementary Figures S1 and S2, available at Annals of Oncology online).
Overall, grade !3 AEs were reported in 75.3% and 61.4% of patients treated with cobimetinib plus vemurafenib and vemurafenib, respectively ( Table 1 The rates of recurrence of specific AEs were variable, and with the exception of rash the majority of patients did not experience a recurrence. In the cobimetinib plus vemurafenib arm, the rates of recurrence of AEs of interest were as follows: rash, 58% of patients (103/179); diarrhoea, 42% (63/150); abnormal LFTs, 41% (46/111); cuSCC and keratoacanthoma, 40% (6/ 15); photosensitivity, 36% (43/118); pyrexia, 34% (24/71); CPK level elevations 32% (28/88); serous retinopathy, 25% (17/67); and LVEF reduction, 24% (7/29).
Management of AEs
Most AEs were managed with dose modifications (dose reduction or interruption). Similar proportions of patients had dose modifications for cobimetinib (57.1%) and vemurafenib (61.5%; Table 2 ) and approximately half the patients had dose modifications for both drugs (47.0%). The most common AEs leading to Adapted from The Lancet, Ascierto PA et al., "Overall survival with cobimetinib combined with vemurafenib in advanced BRAF V600 -mutated melanoma: updated efficacy results from the phase 3, randomised coBRIM study," with permission from Elsevier [9] . a At the time of the primary analysis [10] , eight patients randomly assigned to the vemurafenib arm were believed to have received cobimetinib owing to site medication dispensing error; therefore, they were included in the cobimetinib plus vemurafenib arm. It was later established, however, that seven of these eight patients did not in fact receive cobimetinib. These seven patients were reassigned to the vemurafenib arm. Hence, for the safety population at the time of this update, relative to the original report of this study [10] , the safety denominators for the two arms have changed from 254 to 247 for the cobimetinib plus vemurafenib arm and from 239 to 246 for the vemurafenib arm. b Combined terms include (in decreasing order of reported incidence) the preferred terms rash, rash maculopapular, erythema, dermatitis acneiform, folliculitis, rash macular, rash papular, rash erythematous, acne, dermatitis, rash pruritic, furuncle, rash generalized, dermatitis allergic, rash follicular, rash pustular, dermatitis exfoliative, generalized erythema, rash morbilliform, and drug eruption. c Combined terms include the MedDRA high-level terms for photosensitivity and photodermatosis conditions. d Combined terms include (in decreasing order of reported incidence) the preferred terms chorioretinopathy, retinal detachment, detachment of retinal pigment epithelium, macular oedema, macular fibrosis, retinal disorder, retinopathy, subretinal fluid, and detachment of macular retinal pigment epithelium. AE, adverse event; cuSCC, cutaneous squamous cell carcinoma; MedDRA, Medical Dictionary for Regulatory Activities.
dose modification for either drug (!5%) in the cobimetinib plus vemurafenib arm included rash, diarrhoea, pyrexia, serous retinopathy, elevated CPK, and abnormal LFTs. In the cobimetinib plus vemurafenib arm, discontinuation rates for any AE were 21.5% for cobimetinib, 17.8% for vemurafenib, and 16.6% for the combination.
Notably, for LFTs, vemurafenib dosing was the most frequently modified. Elevated CPK level was managed conservatively, with interruption or reduction of cobimetinib for grade !3 events when appropriate, and drug discontinuation was uncommon. Few patients required dose modification for photosensitivity. Most events of serous retinopathy were managed by close observation, with modification of cobimetinib dosing when appropriate. One case of retinal ischemia was reported in the cobimetinib plus vemurafenib arm and one case of retinal vascular disorder in the vemurafenib arm. Both patients continued with their study treatment, and the retinal ischaemia event subsequently resolved.
In the case of LVEF reduction, the cobimetinib dose was more likely to be modified or discontinued in the cobimetinib plus vemurafenib arm (Table 2) .
Events usually managed with additional supportive care options included diarrhoea [typically managed with antidiarrheal agents (usually loperamide)], pyrexia (antipyretics), and epithelial proliferation AEs such as cuSCC and keratoacanthoma, for which simple complete excision was common.
Time to resolution
Most of the common AEs resolved relatively rapidly, with a median time to resolution of <2 months. For example, the median time to resolution for all-grade diarrhoea, pyrexia, and cuSCC was <1 month in both treatment arms (Figure 4) , and the median time to resolution for all-grade elevated CPK and abnormal LFTs was <2 months in both arms. Figure 1 . Incidence of select AEs by cycle in patients who received cobimetinib plus vemurafenib. If the patient has two reports of the same AE that started at different cycles, they are counted at both cycles. If the patient has one AE that lasts for two cycles, it is only reported once at onset. The vemurafenib data are in supplementary Figure S2 , available at Annals of Oncology online. AEs, adverse events; ALT, alanine aminotransferase; CPK, creatine phosphokinase; cuSCC, cutaneous squamous cell carcinoma. Figure 2 . Box and whisker plots showing the median, first and third quartile, and range for the onset of first incidence of AEs of interest (any grade) in months. Data for the cobimetinib plus vemurafenib arm and for the vemurafenib arm are displayed. The data for rash includes the preferred terms acne, acne conglobata, acne cosmetica, acne cystic, acne fulminans, acne infantile, acne occupational, acne pustular, acne varioliformis, application site acne, chloracne, dermatitis acneiform, iodo acne, mechanical acne, oil acne, eyelid folliculitis, folliculitis, furuncle, rash follicular, rash pustular, dermatitis, dermatitis allergic, dermatitis bullous, dermatitis exfoliative, drug eruption, erythema, exfoliative rash, generalized erythema, rash, rash erythematous, rash generalized, rash macular, rash maculopapular, rash maculovesicular, rash morbilliform, rash papular, rash papulosquamous, rash pruritic, rash vesicular, and toxic skin eruption. Data for photosensitivity includes MedDRA high-level terms for photosensitivity and photodermatosis conditions. Data for elevated CPK includes the preferred terms blood CPK increased and rhabdomyolysis. Data for serous retinopathy includes the preferred terms chorioretinal disorder, chorioretinopathy, detachment of macular retinal pigment epithelium, detachment of retinal pigment epithelium, macular fibrosis, macular oedema, retinal detachment, retinal disorder, retinal pigment epithelial tear, retinal tear, retinopathy, and scleral buckling surgery. AEs, adverse events; CPK, creatine phosphokinase; cuSCC, cutaneous squamous cell carcinoma; LFT, liver function test; LVEF, left ventricular ejection fraction; MedDRA, Medical Dictionary for Regulatory Activities. Differences in the median time to resolution of certain AEs between arms were observed. The median time for resolution of all-grade rash was slightly longer in patients receiving vemurafenib compared with cobimetinib plus vemurafenib (2.1 and 0.9 months, respectively), as was time to resolution of LVEF decline (5.5 and 2.8 months, respectively). In contrast, the median time to resolution of all-grade photosensitivity was longer in the cobimetinib plus vemurafenib arm (2.5 months) compared with the vemurafenib arm (1.0 months).
In addition, resolution of grade !3 events were documented (supplementary Table S2 , available at Annals of Oncology online); overall, >75% of all grade !3 events in the cobimetinib plus vemurafenib arm resolved by the time of data cut-off, with the exception of pyrexia (60%) and serous retinopathy (43%). Grade !3 rash resolved within 3 months of onset in 87% and 84% of events in the cobimetinib plus vemurafenib and the vemurafenib arms, respectively.
More events of grade !3 diarrhoea in the cobimetinib plus vemurafenib resolved within 1 month of onset (78%). In the cobimetinib plus vemurafenib arm, 97% of cuSCC events were considered resolved at the time of data cut-off. At data cut-off, 82% and 60% of LVEF reduction events (all grades) had resolved in the cobimetinib plus vemurafenib and the vemurafenib arms, respectively.
Discussion
In this expanded safety analysis of the coBRIM study, the reported incidence and severity of AEs for both the cobimetinib plus vemurafenib arm and the vemurafenib arm were similar and consistent with that reported earlier [10] . Most of the common AEs reported were grades 1-2 in both treatment arms. Common grade !3 AEs (reported in >5% of patients) in the cobimetinib plus vemurafenib arm included rash, abnormal LFTs, and diarrhoea. In the vemurafenib arm, common grade !3 AEs included keratoacanthoma and cuSCC. Most of the AEs resolved with dose modifications and conservative management. The rate of treatment discontinuation because of AEs was <20%. With the sole exception of rash, the majority of patients did not experience a recurrence of specific AEs.
The addition of cobimetinib to vemurafenib did not notably affect tolerability of treatment [1, 9] . Proactive management of common AEs in early cycles may have contributed to the reduced incidence and severity of AEs in subsequent cycles. Additionally, the intermittent dosing schedule of cobimetinib might have facilitated recovery from AEs without intervention. Supplementary Table S3 , available at Annals of Oncology online summarizes AE management strategies from coBRIM; physicians should consult their local prescribing information for appropriate AE management [1] [2] [3] [4] . A distinct temporal pattern-onset within the first few cycles of treatment followed by a decline in incidence thereafter-was observed with gastrointestinal AEs, rash, pyrexia, and CPK and ALT/AST elevations. A similar pattern was observed for the first onset of grade !3 AEs. Other common AEs (photosensitivity, GGT level increase, cuSCC, and keratoacanthomas) displayed no clear temporal pattern, and events occurred throughout the course of treatment.
The incidence of serous retinopathy was influenced by proactive monitoring and identification of asymptomatic AEs. Approximately 57% of the cases of serous retinopathy reported in this study were asymptomatic (grade 1) and were identified during routine monitoring. Approximately two-thirds of CPK AEs (of 94 overall) in coBRIM were asymptomatic and were discovered by routine monitoring. Higher-grade events (grade !3) were responsive to dose modification or treatment discontinuation, and three of seven events had resolved by the data cut-off.
Cobimetinib plus vemurafenib shared a number of common AEs reported with other BRAFi and MEKi combinations, including diarrhoea, nausea, rash, pyrexia, and vomiting [13, 14] . Although direct comparative studies are lacking, differences in the presentation of common AEs have been noted. Photosensitivity and LFT abnormalities may occur more frequently with cobimetinib plus vemurafenib than with dabrafenib and trametinib [13] . However, events of photosensitivity reported in the coBRIM study were all grade 1 or 2 and were managed conservatively with preventive use of sunscreen or other sun protection measures; dose modification for either drug was needed in <3% of patients and only one patient discontinued treatment because of photosensitivity. Likewise, clinically significant LFT abnormalities (AST or ALT >3Â ULN þ total bilirubin >2Â ULN) were uncommon (<1%). The median time to resolution (all grades) was <2 months, with 64% of events resolved by 3 months and 79% by the time of data cut-off. A similar pattern was observed for grade 3/4 events. The incidence of pyrexia in the vemurafenib arm of this study was similar to that observed with dabrafenib in a similar patient population [13, 15] . However, pyrexia occurred more frequently in patients with melanoma receiving the dabrafenib and trametinib combination, with 51%-63% of patients experiencing >1 grade !2 AE [13, 15] , compared with 34% of patients experiencing recurrent episodes with the cobimetinib plus vemurafenib combination in this study.
MEKi-associated AEs of LVEF reduction, elevated CPK level, and serous retinopathy have also been observed with other combinations [12] [13] [14] 16] . LVEF reduction rates seem comparable across trials. Importantly, no cases of cardiomyopathy were reported in the cobimetinib plus vemurafenib arm. It is difficult to compare rates of CPK level elevation and serous retinopathy because of the lack of proactive prospective monitoring in other trials. Routine/periodic testing for CPK levels and ophthalmologic exams are recommended in order to monitor for the potential of rhabdomyolysis or serous retinopathy, respectively [1] [2] [3] [4] .
In conclusion, this expanded safety analysis broadens the overall safety profile of cobimetinib plus vemurafenib and provides additional evidence that the combination is generally tolerable in patients with advanced BRAF V600 -mutated melanoma with appropriate dose modification for the management of AEs. Patient and provider education in the management of expected AEs is important for prevention and reducing their impact. The favourable safety profile and significantly improved patient outcomes, including objective response rate, duration of response, PFS, and OS, support the use of cobimetinib plus vemurafenib as a standard of care for the initial treatment of patients with advanced BRAF V600 -mutated melanoma.
